Cargando…
Acid-suppressive therapy among infants and risk of anemia at 12 months of age
OBJECTIVES: Numerous studies have shown that links exist between exposure to acid suppression among adults and nutritional deficiencies, especially vitamin B12 and iron. While the use of acid suppression among children and infants is common, nutritional deficiency remains a concern but does not have...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465608/ https://www.ncbi.nlm.nih.gov/pubmed/36105547 http://dx.doi.org/10.1177/20503121221123117 |
_version_ | 1784787835944960000 |
---|---|
author | Abu-Sulb, Ahmad Al-Najjar, Rawan Maghnam, Rama Ashhab, Ashraf |
author_facet | Abu-Sulb, Ahmad Al-Najjar, Rawan Maghnam, Rama Ashhab, Ashraf |
author_sort | Abu-Sulb, Ahmad |
collection | PubMed |
description | OBJECTIVES: Numerous studies have shown that links exist between exposure to acid suppression among adults and nutritional deficiencies, especially vitamin B12 and iron. While the use of acid suppression among children and infants is common, nutritional deficiency remains a concern but does not have numerous studies to support it. We conducted a cohort study to examine this concern; the hypothesis we proposed is that acid-suppressive therapy (AST) during infancy is linked to anemia in the first year of life. METHODS: This retrospective cohort study included infants born between 2017 and 2018 who visited Legacy Community Health. The inclusion criteria were exposure to acid suppression for a minimum of 1 month and a hemoglobin reading at 12–15 months. Infants who had hemoglobinopathies, failure to thrive, or malabsorption syndromes were excluded. Mean hemoglobin was calculated, and student’s t-test was applied to find statistical differences between the two groups. Change in weight before and after treatment was recorded. Occurrence of respiratory and gastroenterological adverse events was recorded in the exposed group. RESULTS: Overall, 135 exposed infants were identified 135 controls were selected. The majority of the sample included Hispanic girls. Ranitidine was the most commonly prescribed medicine. The duration of treatment was 3 months. Weight improved significantly at termination of the treatment. There was no significant difference between the hemoglobin level of cases and controls, and both were not considered anemic. CONCLUSION: AST was not linked to anemia, despite the slightly lower hemoglobin in some cases. There were few weaknesses in our study; therefore, further studies can examine this link by focusing further on medication type and close follow-up. We found that although proton pump inhibitors are considered the first line of treatment, histamine-2 receptor antagonists were more frequently prescribed. Strategies to familiarize general pediatricians with the NSAPGHAN guidelines might be needed. |
format | Online Article Text |
id | pubmed-9465608 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-94656082022-09-13 Acid-suppressive therapy among infants and risk of anemia at 12 months of age Abu-Sulb, Ahmad Al-Najjar, Rawan Maghnam, Rama Ashhab, Ashraf SAGE Open Med Original Research Article OBJECTIVES: Numerous studies have shown that links exist between exposure to acid suppression among adults and nutritional deficiencies, especially vitamin B12 and iron. While the use of acid suppression among children and infants is common, nutritional deficiency remains a concern but does not have numerous studies to support it. We conducted a cohort study to examine this concern; the hypothesis we proposed is that acid-suppressive therapy (AST) during infancy is linked to anemia in the first year of life. METHODS: This retrospective cohort study included infants born between 2017 and 2018 who visited Legacy Community Health. The inclusion criteria were exposure to acid suppression for a minimum of 1 month and a hemoglobin reading at 12–15 months. Infants who had hemoglobinopathies, failure to thrive, or malabsorption syndromes were excluded. Mean hemoglobin was calculated, and student’s t-test was applied to find statistical differences between the two groups. Change in weight before and after treatment was recorded. Occurrence of respiratory and gastroenterological adverse events was recorded in the exposed group. RESULTS: Overall, 135 exposed infants were identified 135 controls were selected. The majority of the sample included Hispanic girls. Ranitidine was the most commonly prescribed medicine. The duration of treatment was 3 months. Weight improved significantly at termination of the treatment. There was no significant difference between the hemoglobin level of cases and controls, and both were not considered anemic. CONCLUSION: AST was not linked to anemia, despite the slightly lower hemoglobin in some cases. There were few weaknesses in our study; therefore, further studies can examine this link by focusing further on medication type and close follow-up. We found that although proton pump inhibitors are considered the first line of treatment, histamine-2 receptor antagonists were more frequently prescribed. Strategies to familiarize general pediatricians with the NSAPGHAN guidelines might be needed. SAGE Publications 2022-09-08 /pmc/articles/PMC9465608/ /pubmed/36105547 http://dx.doi.org/10.1177/20503121221123117 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Article Abu-Sulb, Ahmad Al-Najjar, Rawan Maghnam, Rama Ashhab, Ashraf Acid-suppressive therapy among infants and risk of anemia at 12 months of age |
title | Acid-suppressive therapy among infants and risk of anemia at
12 months of age |
title_full | Acid-suppressive therapy among infants and risk of anemia at
12 months of age |
title_fullStr | Acid-suppressive therapy among infants and risk of anemia at
12 months of age |
title_full_unstemmed | Acid-suppressive therapy among infants and risk of anemia at
12 months of age |
title_short | Acid-suppressive therapy among infants and risk of anemia at
12 months of age |
title_sort | acid-suppressive therapy among infants and risk of anemia at
12 months of age |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465608/ https://www.ncbi.nlm.nih.gov/pubmed/36105547 http://dx.doi.org/10.1177/20503121221123117 |
work_keys_str_mv | AT abusulbahmad acidsuppressivetherapyamonginfantsandriskofanemiaat12monthsofage AT alnajjarrawan acidsuppressivetherapyamonginfantsandriskofanemiaat12monthsofage AT maghnamrama acidsuppressivetherapyamonginfantsandriskofanemiaat12monthsofage AT ashhabashraf acidsuppressivetherapyamonginfantsandriskofanemiaat12monthsofage |